ClinicalTrials.gg
RecruitingNCT07560748ProPCIUpdated Sep 10, 2026

Prospective Prostate Cancer Infrastructure

An observational study in High Risk Localized Prostate Cancer and Synchronous Metastatic Hormone-Sensitive Prostate Cancer, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Radboud University Medical Center · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 23 studies in Prostatic Neoplasms by Radboud University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · Radboud University Medical Center.

Started
2026
the only one that year
Observational
9 of 23
2 open now
Registered
23rd of 23
by date

Among the 23 studies in Prostatic Neoplasms by Radboud University Medical Center, this one is the only one that started in 2026, is one of 9 observational ones, and was the 23rd registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Radboud University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Radboud University Medical Center, or all of them as a file.
02

Study summary

The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer. This will help to better understand how these patients are treated in daily practice, how treatments affect quality of life, and facilitate biomarker discovery. The infrastructure is also designed to enable future cohort multiple randomized controlled trials.

03

Conditions studied

  • High Risk Localized Prostate Cancer
  • Synchronous Metastatic Hormone-Sensitive Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

All patients with treatment-naive high-risk localized and treatment-naive metastatic prostate carcinoma will be eligible to participate. These patients are identified by their treating physicians in all participating hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of either: high-risk localized prostate cancer (any of the following: PSA > 20 ng/mL, ISUP Grade Group 4 or 5, or clinical stage ≥ T2c); or prostate cancer confirmed by imaging (CT, bone scintigraphy, PSMA PET/CT, or (whole-body) MRI in combination with tumor markers (PSA)), or by of a metastatic lesion histopathologically deemed to be of prostatic origin.
  • Prostate adenocarcinoma (our main focus). We will allow the inclusion of adenocarcinoma with mixed small- or large-cell neuroendocrine prostate
  • Age ≥ 18 years at the time of inclusion.
  • Written
  • Able to understand one of the following languages sufficiently: Dutch, English, Arabic or Turkish.

Exclusion criteria

Exclusion Criteria:

  • Not currently living in the Netherlands.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Target follow-up
48 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Treatment patterns

    Documentation of initial and sequential treatment strategies, including type, timing, and combination of androgen deprivation therapy, androgen receptor pathway inhibitors, chemotherapy, and radiotherapy, within 4 months and beyond 4 months after diagnosis.

    Time frame: From diagnosis through study completion, up to 4 years

  2. PSA response

    Proportion of patients achieving \>50% and \>90% PSA decline from baseline within the first year after treatment initiation.

    Time frame: From treatment initiation up to 12 months.

  3. PSA nadir

    Lowest PSA value achieved within 1 year after treatment initiation and time from treatment initiation to PSA nadir.

    Time frame: From treatment initiation up to 12 months

  4. Utilization of imaging modalities for primary staging

    Type and frequency of imaging modalities used at primary staging, including PSMA PET/CT, conventional CT, bone scintigraphy, and MRI.

    Time frame: At baseline

  5. Time to clinical progression

    Time from treatment initiation to clinical progression, defined as local progression, and/or symptomatic skeletal events (pain, fracture, spinal cord compression), or initiation of surgery or radiotherapy for progression.

    Time frame: From treatment initiation through study completion, up to 4 years

  6. Time to biochemical progression

    Time from treatment initiation to biochemical progression per PCWG3 criteria, defined as a minimum PSA rise of 25% AND an absolute increase of 2ng/mL from the nadir, confirmed on two measurements ≥3 weeks apart.

    Time frame: From treatment initiation through study completion, up to 4 years

  7. Time to radiographic progression

    Time from treatment initiation to radiographic progression based on imaging (conventional imaging, PSMA PET/CT), or RECIST 1.1 criteria.

    Time frame: From treatment initiation through study completion, up to 4 years

  8. Time to castration-resistant prostate cancer (CRPC)

    Time from treatment initiation to castration-resistant prostate cancer (CRPC) per PCWG3 criteria.

    Time frame: From treatment initiation through study completion, up to 4 years

  9. Overall survival

    Time from diagnosis to death from any cause.

    Time frame: From diagnosis through study completion, up to 4 years

  10. Adverse events

    Type, grade, and treatment-relatedness of adverse events occurring during treatment, graded according to the Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: From treatment initiation through study completion, up to 4 years

  11. Number of hospital admissions

    Total number of planned and unplanned hospital admissions.

    Time frame: From treatment initiation through study completion, up to 4 years

  12. Number of outpatient visits

    Total number of outpatient visits

    Time frame: From treatment initiation through study completion, up to 4 years

Secondary outcomes

  1. Dynamic change in ctDNA fraction

    Change in ctDNA fraction at 4-6 weeks and 9 months after start of initial treatment.

    Time frame: Change from baseline at 4-6 weeks, and 9 months after start of initial treatment.

  2. Prevalence and clinical phenotypes of genomic alterations

    Prevalence and clinical phenotype associations of somatic alterations in prostate cancer related genes and (likely) pathogenic germline variants, detected by cfDNA or tumor tissue.

    Time frame: At diagnosis or at disease progression, up to 4 years

  3. Health-Related Quality of Life (Global Health Status)

    Clinically meaningful change in Global Health Status using the EORTC QLQ-C30 as a measure for Health Related Quality of Life, from baseline to sequential follow-up.

    Time frame: Change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.

  4. Health-Related Quality of Life (Health Utility)

    Change in health utility index and EQ Visual Analogue Scale score measured using the EQ-5D-5L, across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months

  5. Pain intensity and interference

    Change in average pain score and pain interference score measured using the Brief Pain Inventory - Short Form (BPI-SF).

    Time frame: Change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.

  6. Fatigue severity and interference

    Change in average fatigue score and fatigue interference score measured using the Brief Fatigue Inventory (BFI).

    Time frame: Change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.

  7. Prostate cancer-specific symptoms

    Change in prostate cancer-specific symptoms measured using the EORTC QLQ-PR25, domain scores for urinary symptoms, bowel symptoms, hormonal treatment-related symptoms, sexual activity, and sexual functioning.

    Time frame: Change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wissing RO, van Elst T, Sedelaar M, Smeenk RJ, van den Berg P, van Dodewaard-de Jong JM, Lont AP, Hendriks MP, Luijendijk-de Bruin D, van de Luijtgaarden ACM, Roelofs LAJ, Vis AN, Hoekstra RJ, Bloemendal HJ, van Basten JA, Mehra N. PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI 'trials within cohorts' study. BMJ Open. 2026 Sep 11;16(9):e121662. doi: 10.1136/bmjopen-2026-121662. PubMed 42731831 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 48 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 48 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
May 1, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2030
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560748
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Sep 1, 2026
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Sep 10, 2026

Study contacts

Niven Mehra, PhD
Contact
niven.mehra@radboudumc.nl
+3124 361 88 00
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion